论文部分内容阅读
[目的]探讨无创双水平正压通气(BiPAP)联合呼吸兴奋剂治疗慢性阻塞性肺疾病(COPD)合并轻、中度肺性脑病的临床疗效及对炎症因子的影响.[方法]收集本院2013年12月至2015年12月收治的COPD合并轻、中度肺性脑病患者80例,随机分为观察组与对照组.两组患者均给予常规对症支持和BiPAP治疗,且观察组加用呼吸兴奋剂进行治疗.记录两组患者接受治疗前后各指标的变化情况.[结果]观察组治疗24 h后动脉血氧分压 (PaO2)水平高于对照组,二氧化碳分压 (PaCO2)水平低于对照组(P<0.05);治疗后观察组患者血氧饱和度 (SaO2) 高于对照组,呼吸频率 (RR) 、心率 (HR)低于对照组 (均P<0.05);观察组患者白细胞介素6(IL-6)、白细胞介素8(IL-8)及白细胞介素10(IL-10)水平均显著低于对照组,其差异有统计学意义(均P<0.05);观察组通气时间、恢复意识时间、住院时间短于对照组(均P<0.05),气管插管率均低于对照组(P<0.05);观察组治疗有效率为90.0%,明显高于对照组47.5%,其差异有统计学意义(P<0.05).[结论]应用BiPAP联合呼吸兴奋剂治疗COPD合并肺性脑病疗效佳,可有效减少气管插管率,缩短住院时间,值得临床推广应用.“,”[Objective]To investigate the changes of the inflammation factor levels and the clinical effect of noninvasive bi-level positive airway pressure (BiPAP) combined with respiratory stimulant treatment on COPD patients with mild to moderate pulmonary encephalopathy.[Methods]A total of 80 patients with COPD and mild to moderate pulmonary encephalopathy at the Central Hospital of Jiangjin District between December 2013 and December 2015 were randomly divided into the observation group (n=40) and the control group (n=40).Patients in both groups received routine supportive treatments in addition to BiPAP ventilation while the observation group was treated with respiratory stimulant.A variety of the indicators (PaO2,PaCO2,SaO2,RR,HR) was recorded before and after treatment in two groups.[Results]After 24 hours of treatment,PaO2 and SaO2 in the observation group improved significantly more than those in the control group (P<0.05).PaCO2,RR and HR were significantly lower in the observation group than in the control group,and aeration time,consciousness recovery time,hospital stay and tracheal intubation rate were significantly shorter (all P<0.05).The levels of IL-6,IL-8 and IL-10 in the observation group were significantly lower than those in the control group (all P<0.05).The effective rate of the observation group was 90.0%,which was higher than that of the control group (47.5%);it showed statistical significance (P<0.05).[Conclusion]Application of BiPAP combined with respiratory stimulants is an effective treatment for COPD patients with pulmonary encephalopathy.It can reduce the tracheal intubation rate and shorten the hospitalization time.